Lapatinib was the first HER2-targeting TKI approved for the treatment of HER2+ breast cancer and is a reversible dual inhibitor of epidermal growth factor receptor (EGFR) and HER2 [8]. This evidence concerns the gene EGFR and breast carcinoma.